Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 1/20 | 0.36 |
| ▸ | CES2 | O00748 | 1/20 | 0.31 |
| ▸ | CES1 | P23141 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29918982 | 1.00 | HDAC4 (0.36) | HDAC4CES2CES1ALDH1A1ACHE | |
| SCHEMBL2329832 | 0.81 | ALDH1A1 (0.32) | ALDH1A1ACHE | |
| SCHEMBL29449513 | 0.81 | ALDH1A1 (0.32) | ALDH1A1ACHE | |
| SCHEMBL21996002 | 0.80 | TNF (0.33) | — | |
| SCHEMBL31567045 | 0.80 | TNF (0.33) | — | |
| SCHEMBL584965 | 0.79 | KDM1A (0.33) | ALDH1A1ACHE | |
| SCHEMBL29620414 | 0.79 | ALDH1A1 (0.31) | ALDH1A1ACHE | |
| SCHEMBL29636024 | 0.79 | KDM1A (0.33) | ALDH1A1ACHE | |
| SCHEMBL10871807 | 0.79 | ALDH1A1 (0.31) | ALDH1A1ACHE | |
| SCHEMBL5733860 | 0.79 | ALDH1A1 (0.36) | HDAC4ALDH1A1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122059801-A | Synthesis method of Marbalol Sha Wei side chain intermediate | 重庆圣华曦药业股份有限公司 | 2026-05-19 | — | — | CN | claimed |
| CN-117049938-B | Preparation method of 6-bromo-2, 3-difluorotoluene | 山东轩德医药科技有限公司 | 2024-06-14 | — | — | CN | claimed |
| CN-117049938-A | Preparation method of 6-bromo-2, 3-difluorotoluene | 山东轩德医药科技有限公司 | 2023-11-14 | — | — | CN | claimed |
| CN-115677656-A | Preparation method of baroxavir key intermediate | 南通常佑药业科技有限公司 | 2023-02-03 | — | — | CN | claimed |
| CN-122059801-A | Synthesis method of Marbalol Sha Wei side chain intermediate | 重庆圣华曦药业股份有限公司 | 2026-05-19 | — | — | CN | disclosed |
| EP-4724438-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | Remix Therapeutics Inc. (US) | 2026-04-15 | — | — | EP | disclosed |
| EP-4699607-A2 | N-(HYDROXYALKYL (HETERO)ARYL) TETRAHYDROFURAN CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | Vertex Pharmaceuticals Incorporated (US) | 2026-02-25 | — | — | EP | disclosed |
| US-20260001877-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2026-01-01 | — | — | US | disclosed |
| WO-2025264645-A1 | SODIUM CHANNEL BLOCKING COMPOUNDS, DERIVATIVES THEREOF, AND METHODS OF THEIR USE | LATIGO BIOTHERAPEUTICS, INC. (US) | 2025-12-26 | — | — | WO | disclosed |
| US-20250353836-A1 | N-(HYDROXYALKYL (HETERO)ARYL) TETRAHYDROFURAN CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMA (US) | 2025-11-20 | — | — | US | disclosed |
| EP-4347031-B1 | N-(HYDROXYALKYL (HETERO)ARYL) TETRAHYDROFURAN CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMA (US) | 2025-10-29 | — | — | EP | disclosed |
| US-12441703-B2 | Carboxamides as modulators of sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-10-14 | — | — | US | disclosed |
| WO-2010118208-A1 | BENZOXAZEPIN-4- (5H) -YL DERIVATIVES AND THEIR USE TO TREAT CANCER | EXELIXIS, INC. (US) | 2010-10-14 | — | — | WO | disclosed |
| WO-2010118208-A1 | BENZOXAZEPIN-4- (5H) -YL DERIVATIVES AND THEIR USE TO TREAT CANCER | EXELIXIS, INC. (US) | 2010-10-14 | — | — | WO | disclosed |
| US-20100234324-A1 | Quinazolinamide derivatives | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-09-16 | — | — | US | disclosed |
| WO-2009117097-A1 | NOVEL TYROSINE KINASE INHIBITORS | CHEMBRIDGE CORPORATION (US) | 2009-09-24 | — | — | WO | disclosed |
| WO-2009117097-A1 | NOVEL TYROSINE KINASE INHIBITORS | CHEMBRIDGE CORPORATION (US) | 2009-09-24 | — | — | WO | disclosed |
| EP-1514864-B1 | Difluoralkyl aromatic compounds | SALTIGO GMBH (DE) | 2008-03-19 | — | — | EP | disclosed |
| EP-1514864-A2 | Difluoralkyl aromatic compounds | Bayer Chemicals AG (DE) | 2005-03-16 | — | — | EP | disclosed |
| US-20050054733-A1 | Difluoroalkylaromatics | LANXESS DEUTSCHLAND GMBH (DE) | 2005-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260001877-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | CNR1, SCN1B, OPRL1 | HDAC4 2101/4885CES2 531/4885CES1 547/4885 |
| US-12441703-B2 | Carboxamides as modulators of sodium channels | TRPV1, SCN2A, SCN10A | HDAC4 333/4885CES2 789/4885CES1 1445/4885 |
| US-20050054733-A1 | Difluoroalkylaromatics | NQO1, TYR, FLI1 | HDAC4 1441/4885CES2 141/4885CES1 961/4885 |
| US-20100234324-A1 | Quinazolinamide derivatives | HSP90AB1, HSP90AA1, HSP90AB2P | HDAC4 1014/4885CES2 2105/4885CES1 1403/4885 |
| US-20250353836-A1 | N-(HYDROXYALKYL (HETERO)ARYL) TETRAHYDROFURAN CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | TRPV1, SCN2A, SCN2B | HDAC4 506/4885CES2 671/4885CES1 2091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.